Acute Application of Pegvisomant and Octreotide in Acromegaly
NCT ID: NCT00595140
Last Updated: 2008-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
10 participants
INTERVENTIONAL
2008-01-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
patients with acromegaly on stable pegvisomant therapy
pegvisomant
growth hormone receptor antagonist pegvisomant in patients´ individual dose
2
Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg
combination with somatostatin analogue octreotide
s.c., 100µg, one time
3
Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally
combination with dopamine agonist cabergoline
oral, 0.5mg, one time
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pegvisomant
growth hormone receptor antagonist pegvisomant in patients´ individual dose
combination with somatostatin analogue octreotide
s.c., 100µg, one time
combination with dopamine agonist cabergoline
oral, 0.5mg, one time
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with diabetes mellitus may be included. Glucose levels must be controlled regularly throughout the study
* patients must not be co-treated with any other medication for acromegaly
Exclusion Criteria
* any relevant acute disease
* history of hypersensitivity against any of the used drugs
* pregnancy or lactation
* abnormal baseline findings
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ludwig-Maximilians - University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medizinische Klinik - Innenstadt of the University of Munich
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jochen Schopohl, MD
Role: PRINCIPAL_INVESTIGATOR
Medizinische Klinik - Innenstadt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Klinik - Innenstadt of the University of Munich
Munich, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT-Nr. 2007-005585-12
Identifier Type: -
Identifier Source: secondary_id
EudraCT-Nr. 2007-005585-12
Identifier Type: -
Identifier Source: org_study_id